-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
The Power of Dual Immunotherapy
The Power of Dual Immunotherapy
NORTHAMPTON, MA / ACCESSWIRE / January 27, 2023 / Originally published on Bristol Myers Squibb News & Perspectives
A decade ago, the evolution of immuno-oncology transformed the landscape of therapy for patients with many cancers. Although individual immunotherapies have helped to improve outcomes for patients, the addition of rational combinations of more than one immunotherapy regimen has led to more treatment options and the potential for longer survival.
Not all patients have been reached by these advances though and there is an urgency to achieve more.
Bristol Myers Squibb has been a pioneer in bringing immunotherapy, including dual immunotherapy combinations, forward to patients, and continues to examine the immune system from multiple perspectives in order to find potentially complementary combinations of therapies.
Building upon existing therapies that overcome immune inhibition
Bristol Myers Squibb has pursued a number of ways to address the immune response and leverage it to attack tumors. CTLA-4 and PD-1 are immune checkpoints that inhibit the immune response and, in a healthy person, work to keep the immune system in check. In patients with cancer, tumor cells can potentially manipulate immune checkpoints to evade attack from T cells, or the body's immune response. Existing therapies have successfully leveraged inhibition of these immune checkpoints to release the "brakes" from T cells and allow them to recognize and to attack tumors.
LAG-3 is another immune checkpoint, and it is a focus of research efforts at Bristol Myers Squibb. LAG-3, a protein found on the surface of certain T cells, may promote T cell exhaustion, which can allow tumors to evade the immune system. Researchers have found that blocking the LAG-3 receptor on T cells may help them to overcome exhaustion, another way of releasing the "brakes" from T cells.
The strategy of leveraging LAG-3 to fight cancer seems particularly promising when used in combination with existing immunotherapies. The decision to pursue various combinations is made based on scientific rationale and deep knowledge of how different mechanisms of action can work together.
Bristol Myers Squibb is exploring doublet and triplet combinations that bring together LAG-3 with existing therapies. We believe we have the opportunity to leverage therapies with similar mechanisms of action, as well as those with complementary mechanisms of action.
Exploring the promise of immunostimulatory therapy
Research has also focused on immunotherapies that directly stimulate the immune system, as opposed to those that work by overcoming inhibition of the immune response. For example, therapies leveraging the IL-2 pathway may directly activate, or agonize, the immune system. They step on the "gas" of the immune system.
"We believe that immunostimulatory therapies may show promise when used in combination with existing therapies that overcome immune inhibition. We are well positioned to bring these types of dual immunotherapy regimens forward," said Gary Grossfeld, Global Development Project Leader at Bristol Myers Squibb. "Leveraging more than one pathway can potentially improve the immune system response to cancer, thereby building on the efficacy of single agent therapy while maintaining a favorable safety profile."
The importance of precision medicine
Part of bringing new therapies forward is ensuring that they are targeted to specific diseases and patient populations.
Certain biomarkers - whether genetic or protein based - may give an indication that one type of therapy or combination will work better in some patients versus others.
"Our study protocols are filled with exploratory biomarker work aimed at understanding which patients are likely to benefit from certain treatments. We are dedicated to a precision medicine approach in our development programs, and I expect we may see great progress in the next several years," said Grossfeld.
Grossfeld believes that a focus on precision medicine, as well as a strategic approach to building on existing therapies with investigational agents, have positioned Bristol Myers Squibb at the forefront of immuno-oncology research. Despite advances in treatment of cancer with immunotherapy, a large number of unmet clinical needs remain. The goal is always to move the needle for patients.
View additional multimedia and more ESG storytelling from Bristol Myers Squibb Company on 3blmedia.com.
Contact Info:
Spokesperson: Bristol Myers Squibb Company
Website:
Email: info@3blmedia.com
SOURCE: Bristol Myers Squibb Company
View source version on accesswire.com:
NORTHAMPTON, MA / ACCESSWIRE / January 27, 2023 / Originally published on Bristol Myers Squibb News & Perspectives
马萨诸塞州北安普敦/ACCESSWIRE/2023 年 1 月 27 日/ 最初发表在 Bristol Myers Squibb 新闻与展望上
A decade ago, the evolution of immuno-oncology transformed the landscape of therapy for patients with many cancers. Although individual immunotherapies have helped to improve outcomes for patients, the addition of rational combinations of more than one immunotherapy regimen has led to more treatment options and the potential for longer survival.
十年前,免疫肿瘤学的演变改变了许多癌症患者的治疗格局。尽管个体免疫疗法有助于改善患者的预后,但添加多个免疫疗法方案的合理组合可带来更多的治疗选择和更长的存活率。
Not all patients have been reached by these advances though and there is an urgency to achieve more.
但是,并非所有患者都能从这些进展中受益,迫切需要取得更多成就。
Bristol Myers Squibb has been a pioneer in bringing immunotherapy, including dual immunotherapy combinations, forward to patients, and continues to examine the immune system from multiple perspectives in order to find potentially complementary combinations of therapies.
Bristol Myers Squibb一直是向患者提供免疫疗法(包括双重免疫疗法组合)的先驱,并将继续从多个角度研究免疫系统,以寻找潜在的互补疗法组合。
Building upon existing therapies that overcome immune inhibition
以克服免疫抑制的现有疗法为基础
Bristol Myers Squibb has pursued a number of ways to address the immune response and leverage it to attack tumors. CTLA-4 and PD-1 are immune checkpoints that inhibit the immune response and, in a healthy person, work to keep the immune system in check. In patients with cancer, tumor cells can potentially manipulate immune checkpoints to evade attack from T cells, or the body's immune response. Existing therapies have successfully leveraged inhibition of these immune checkpoints to release the "brakes" from T cells and allow them to recognize and to attack tumors.
Bristol Myers Squibb一直在寻找多种方法来解决免疫反应并利用它来攻击肿瘤。CTLA-4 和 PD-1 是抑制免疫反应的免疫检查点,对于健康的人来说,它们可以控制免疫系统。在癌症患者中,肿瘤细胞有可能操纵免疫检查点以逃避T细胞的攻击或人体的免疫反应。现有疗法成功地利用了对这些免疫检查点的抑制,释放了T细胞的 “制动器”,使它们能够识别和攻击肿瘤。
LAG-3 is another immune checkpoint, and it is a focus of research efforts at Bristol Myers Squibb. LAG-3, a protein found on the surface of certain T cells, may promote T cell exhaustion, which can allow tumors to evade the immune system. Researchers have found that blocking the LAG-3 receptor on T cells may help them to overcome exhaustion, another way of releasing the "brakes" from T cells.
LAG-3 是另一个免疫检查点,也是百时美施贵宝研究的重点。LAG-3 是一种存在于某些 T 细胞表面的蛋白质,可能会促进 T 细胞衰竭,从而使肿瘤逃避免疫系统。研究人员发现,阻断 T 细胞上的 LAG-3 受体可能有助于他们克服疲劳,这是释放 T 细胞 “刹车” 的另一种方式。
The strategy of leveraging LAG-3 to fight cancer seems particularly promising when used in combination with existing immunotherapies. The decision to pursue various combinations is made based on scientific rationale and deep knowledge of how different mechanisms of action can work together.
与现有免疫疗法联合使用时,利用 LAG-3 对抗癌症的策略似乎特别有希望。采用各种组合的决定是基于科学依据和对不同作用机制如何协同作用的深刻了解做出的。
Bristol Myers Squibb is exploring doublet and triplet combinations that bring together LAG-3 with existing therapies. We believe we have the opportunity to leverage therapies with similar mechanisms of action, as well as those with complementary mechanisms of action.
Bristol Myers Squibb 正在探索将 LAG-3 与现有疗法结合在一起的双重和三联组合。我们相信,我们有机会利用具有相似作用机制的疗法以及具有互补作用机制的疗法。
Exploring the promise of immunostimulatory therapy
探索免疫刺激疗法的前景
Research has also focused on immunotherapies that directly stimulate the immune system, as opposed to those that work by overcoming inhibition of the immune response. For example, therapies leveraging the IL-2 pathway may directly activate, or agonize, the immune system. They step on the "gas" of the immune system.
研究还侧重于直接刺激免疫系统的免疫疗法,而不是那些通过克服免疫反应抑制而起作用的免疫疗法。例如,利用IL-2途径的疗法可能会直接激活或激活免疫系统。他们踩在免疫系统的 “气体” 上。
"We believe that immunostimulatory therapies may show promise when used in combination with existing therapies that overcome immune inhibition. We are well positioned to bring these types of dual immunotherapy regimens forward," said Gary Grossfeld, Global Development Project Leader at Bristol Myers Squibb. "Leveraging more than one pathway can potentially improve the immune system response to cancer, thereby building on the efficacy of single agent therapy while maintaining a favorable safety profile."
“我们认为,当与克服免疫抑制的现有疗法结合使用时,免疫刺激疗法可能会显示出希望。我们完全有能力推出这类双重免疫疗法方案。” 百时美施贵宝全球开发项目负责人加里·格罗斯菲尔德说。“利用多种途径有可能改善免疫系统对癌症的反应,从而在保持良好的安全性的同时,在单一药物疗法的疗效基础上再接再厉。”
The importance of precision medicine
精准医疗的重要性
Part of bringing new therapies forward is ensuring that they are targeted to specific diseases and patient populations.
推出新疗法的一部分是确保它们针对特定疾病和患者群体。
Certain biomarkers - whether genetic or protein based - may give an indication that one type of therapy or combination will work better in some patients versus others.
某些生物标志物,无论是基于遗传的还是基于蛋白质的生物标志物,都可能表明,一种疗法或组合在某些患者中比其他患者效果更好。
"Our study protocols are filled with exploratory biomarker work aimed at understanding which patients are likely to benefit from certain treatments. We are dedicated to a precision medicine approach in our development programs, and I expect we may see great progress in the next several years," said Grossfeld.
“我们的研究方案充斥着探索性生物标志物研究,旨在了解哪些患者可能从某些治疗中受益。我们在开发项目中致力于采用精准医疗方法,我预计未来几年我们可能会取得长足的进展,” 格罗斯菲尔德说。
Grossfeld believes that a focus on precision medicine, as well as a strategic approach to building on existing therapies with investigational agents, have positioned Bristol Myers Squibb at the forefront of immuno-oncology research. Despite advances in treatment of cancer with immunotherapy, a large number of unmet clinical needs remain. The goal is always to move the needle for patients.
格罗斯菲尔德认为,对精准医疗的关注以及在研药物的现有疗法基础上再接再厉的战略方法使布里斯托尔·迈尔斯施贵宝站在免疫肿瘤学研究的最前沿。尽管免疫疗法在癌症治疗方面取得了进展,但仍有大量未得到满足的临床需求。我们的目标始终是为患者提供帮助。
View additional multimedia and more ESG storytelling from Bristol Myers Squibb Company on 3blmedia.com.
在 3blmedia.com 上查看来自布里斯托尔·迈尔斯施贵宝公司的更多多媒体和更多 ESG 故事。
Contact Info:
Spokesperson: Bristol Myers Squibb Company
Website:
Email: info@3blmedia.com
联系信息:
发言人:布里斯托尔·迈尔斯施贵宝公司
网站:
电子邮件:info@3blmedia.com
SOURCE: Bristol Myers Squibb Company
来源: 布里斯托尔·迈尔斯施贵宝公司
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧